BioLineRx Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $BLRX in the last 7 days.
No SEC Form 4 filings for $BLRX in the last 30 days.
See all $BLRX insider activity →BioLineRx (BLRX) and Hemispherian AS will present data on GLIX1, a first-in-class oral TET2 activator, at the 31st Society for Neuro-Oncology Annual Meeting. Presentations cover preclinical research and a Phase 1/2a clinical trial for glioblastoma and other solid tumors. The trial began in Q1 2026 under their collaboration.
BioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.
BioLineRx (BLRX) reported 2Q 2026 revenues of $294,000 and a net loss of $4.3 million. The company's GLIX1 clinical trial is progressing, with new data showing synergistic effects with a PARP inhibitor. BioLineRx raised $3.75 million in capital to support development. The trial's Phase I/IIa results are expected in 1H 2027.
Recent BLRX coverage spans financial news, earnings and technology.
The announcement signals continued advancement of GLIX1, which may generate modest investor interest.
Positive preclinical results and trial initiation may boost investor sentiment for BLRX.
Clinical enrollment progress plus new preclinical synergy data and a just-closed $3.75M capital raise are near-term catalysts for BLRX risk and valuation.
Earnings miss on loss expansion may pressure the stock, but modest revenue and cash raise could provide short‑term support.
Small‑cap earnings with modest loss; limited price impact expected.
AlphAI scores every news story that mentions BLRX with an AI model for sentiment and relevance, and aggregates insider trades from BioLineRx Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioLineRx (BLRX) and Hemispherian AS will present data on GLIX1, a first-in-class oral TET2 activator, at the 31st Society for Neuro-Oncology Annual Meeting. Presentations cover preclinical research and a Phase 1/2a clinical trial for glioblastoma and other solid tumors. The trial began in Q1 2026 under their collaboration.
1 min readBioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.
2 min readBioLineRx (BLRX) reported 2Q 2026 revenues of $294,000 and a net loss of $4.3 million. The company's GLIX1 clinical trial is progressing, with new data showing synergistic effects with a PARP inhibitor. BioLineRx raised $3.75 million in capital to support development. The trial's Phase I/IIa results are expected in 1H 2027.
7 min readBioLineRx reported Q2 2026 revenue of $0.3M, unchanged year-over-year, with a net loss of $4.3M. Shares rose 4.49% post-earnings. GLIX1 clinical trials are progressing, and the company secured $3.75M in financing. Cash reserves were $13.1M at quarter-end.
2 min readBioLineRx (BLRX) reported Q2 2026 earnings with $0.00 EPS, matching estimates. Revenue was $294,000, down from $304,000 in Q2 2025. The company had a net loss of $4.3M and $13.1M in cash and equivalents. BioLineRx is focused on oncology and rare disease treatments.
2 min readBioLineRx Ltd. (BLRX) furnished an SEC Form 6-K — earnings release. Exhibit 1 For Immediate Release BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data
2 min readBioLineRx (BLRX) shares fell 4.4% premarket after announcing a $3.75M share offering at $2.78 per ADS, below recent trading levels. The company plans to use proceeds for R&D and corporate purposes. The offering includes warrants for additional shares and is expected to close by August 31, 2026. BLRX is developing therapies in oncology and rare diseases, with its lead asset in a Phase 1/2a trial.
2 min readBioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced a $3.75M registered direct offering of 1.35M ADSs at $2.78 each, with warrants for 2.02M more. Proceeds will fund R&D and working capital. Closing expected Aug 31, 2026. The company also amended outstanding warrants, reducing the exercise price to $2.78 and extending expiration to 2031.
1 min readBioLineRx Ltd. director Sandra Panem filed an initial ownership report, Form 3, detailing a significant number of employee stock options to purchase ordinary shares. These options include various blocks with different exercise prices and expiration dates ranging from 2026 to 2034. Footnotes indicate that older grants through 2024 are fully vested, while a substantial portion of a more recent October 2024 grant will vest quarterly, conditional on continued service.
2 min readBioLineRx Ltd. director Cohen Gal Avraham has filed an initial ownership report detailing employee stock options for 2,055,000 ordinary shares. These options have an exercise price of $0.052 per share and expire on August 14, 2034, granted under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remainder vesting in seven equal quarterly installments, subject to continued service.
2 min read
